During the last session, Lyra Therapeutics Inc (NASDAQ:LYRA)’s traded shares were 0.12 million, with the beta value of the company hitting 0.00. At the end of the trading day, the stock’s price was $10.68, reflecting an intraday gain of 3.89% or $0.4. The 52-week high for the LYRA share is $37.50, that puts it down -251.12 from that peak though still a striking 64.33% gain since the share price plummeted to a 52-week low of $3.81. The company’s market capitalization is $14.15M, and the average intraday trading volume over the past 10 days was 0.41 million shares, and the average trade volume was 652.77K shares over the past three months.
Lyra Therapeutics Inc (LYRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. LYRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -4.78.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Lyra Therapeutics Inc (LYRA) registered a 3.89% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.89% in intraday trading to $10.68, hitting a weekly high. The stock’s 5-day price performance is -20.89%, and it has moved by 99.81% in 30 days. Based on these gigs, the overall price performance for the year is -27.64%. The short interest in Lyra Therapeutics Inc (NASDAQ:LYRA) is 82523.0 shares and it means that shorts have 0.58 day(s) to cover.
The consensus price target of analysts on Wall Street is $0.5, which implies a decrease of -2036.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.5 and $0.5 respectively. As a result, LYRA is trading at a premium of 95.32% off the target high and 95.32% off the low.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -53.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 181.25k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 181.75k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 598k and 195k respectively. In this case, analysts expect current quarter sales to shrink by -69.69% and then drop by -6.79% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.22%. While earnings are projected to return 80.06% in 2025, the next five years will return 42.99% per annum.
LYRA Dividends
Lyra Therapeutics Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Lyra Therapeutics Inc insiders own 0.83% of total outstanding shares while institutional holders control 48.61%, with the float percentage being 49.01%. PERCEPTIVE ADVISORS LLC is the largest shareholder of the company, while 77.0 institutions own stock in it. As of 2024-06-30, the company held over 12.76 million shares (or 19.4891% of all shares), a total value of $3.53 million in shares.
The next largest institutional holding, with 4.77 million shares, is of CITADEL ADVISORS LLC’s that is approximately 7.2912% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.32 million.
